Global Information
회사소개 | 문의 | 위시리스트

원발 경화성 담관염(PSC) 시장 : 규모, 점유율, 동향, 예측(-2023년)

Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023

리서치사 Coherent Market Insights
발행일 2018년 07월 상품 코드 785772
페이지 정보 영문
가격
US $ 4,500 ₩ 5,479,000 PPT Turned PDF (Single User License)
US $ 7,000 ₩ 8,523,000 PPT Turned PDF (Multi-user License)
US $ 10,000 ₩ 12,176,000 PPT Turned PDF (Enterprise User License)


원발 경화성 담관염(PSC) 시장 : 규모, 점유율, 동향, 예측(-2023년) Primary Sclerosing Cholangitis Market - Size, Share, Trends, and Forecast to 2023
발행일 : 2018년 07월 페이지 정보 : 영문

원발 경화성 담관염(PSC) 시장 성장을 촉진하는 주요인으로서 원발 경화성 담관염(PSC) 메커니즘과 위험인자를 밝혀내기 위한 연구개발 주력을 들 수 있습니다.

세계의 원발 경화성 담관염(PSC: Primary Sclerosing Cholangitis) 시장을 조사했으며, 시장 개요, 의약품 및 지역별 시장 규모 추이와 예측, 시장 성장 촉진요인 및 저해요인, 시장 기회, 경쟁 구도, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 목적과 전제조건

  • 조사 목적
  • 전제조건
  • 약어

제2장 시장 개요

  • 보고서 개요
  • 주요 요약

제3장 시장 역학, 파이프라인, PEST 분석

  • 시장 역학
    • 성장 촉진요인
    • 성장 저해요인
    • 시장 기회
  • 영향 분석
  • PEST 분석
  • 파이프라인 분석
  • PSC 지원과 연구에 초점을 맞춘 대응책
  • 3상 임상시험의 중지 이유
  • 직면한 과제 : 희귀질환용 후보의약품
  • 역학

제4장 세계의 원발 경화성 담관염(PSC) 시장 : 의약품별

  • 서론
  • BTT1023
  • GS-9674
  • NGM282
  • OCA
  • Cenicriviroc
  • LUM001
  • DUR928
  • norUDCA
  • HTD 1801
  • IDN-7314
  • STP705

제5장 세계의 원발 경화성 담관염(PSC) 시장 : 지역별

  • 서론
  • 북미
  • 라틴아메리카
  • 유럽
  • 아시아태평양
  • 중동
  • 아프리카

제6장 경쟁 환경

  • 기업 개요
    • Acorda Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • NGM Biopharmaceuticals, Inc.
    • Intercept Pharmaceuticals, Inc.
    • Dr. Falk Pharma GmbH
    • Allergan Plc.
    • Shire Plc.
    • Durect Corporation
    • Conatus Pharmaceuticals, Inc.
    • Sirnaomics, Inc.
    • Shenzhen HighTide Biopharmaceutical Ltd.
  • 애널리스트의 견해

제7장 섹션

  • 참고 문헌
  • 조사 방법
  • Coherent Market Insights에 대해
LSH 19.03.04

Primary sclerosing cholangitis market report provides detailed information about various candidates that are presently in the preclinical and clinical trials by the manufacturers and research organizations. The drug segment will provide quick snapshot about the clinical phase of the study, study outcomes, estimated launch date, and the upcoming drug molecules. Moreover, the report entails information regarding the major events taking place in the global market, thereby gaining insights about drug approvals, merger agreements, and acquisitions undertaken by the manufacturing companies. Also, incidence and prevalence of PSC and its associated conditions at regional as well as global level are provided in the report, thereby indicating the total number of addressable patient pool in the respective regions and market opportunity for the same.

Market Dynamics

Major factors that are expected to augment growth of the primary sclerosing cholangitis market include increasing number of organizations focusing on clinical innovation and scientific progress on understanding the mechanisms and risk factors for primary sclerosing cholangitis (PSC). For instance, the International PSC study group (IPSCSG), founded in 2010, aims to coordinate PSC research projects between leading institutions worldwide, thereby allowing feasible translational research and advancing efficient research. Also, increasing number of clinical and preclinical trials conducted by the research universities and pharmaceuticals companies is expected to favor market growth over the forecast period.

However, failure of drug candidates to provide desired study outcomes and the withdrawal of late phase clinical trials of potential drug molecules are factors hindering the market growth.

Key features of the study:

This report provides in-depth analysis of primary sclerosing cholangitis market and provides pipeline analysis for the same

It elucidates potential opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global primary sclerosing cholangitis market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the primary sclerosing cholangitis market

Detailed Segmentation:

  • Global Primary Sclerosing Cholangitis Market, By Drug:
  • BTT1023
  • GS-9674
  • NGM282
  • OCA
  • Cenicriviroc
  • LUM001
  • DUR928
  • norUDCA
  • HTD1801
  • IDN-7314
  • STP705
  • Global Primary Sclerosing Cholangitis Market, By Region:
  • North America
  • Regional Overview
  • Latin America
  • Regional Overview
  • Europe
  • Regional Overview
  • Asia Pacific
  • Regional Overview
  • Middle East
  • Regional Overview
  • Africa
  • Regional Overview
  • Company Profiles
  • Acorda Therapeutics, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • Gilead Sciences, Inc.
  • NGM Biopharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Dr. Falk Pharma GmbH
  • Allergan Plc.
  • Shire Plc.
  • Durect Corporation
  • Conatus Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • Shenzhen HighTide Biopharmaceuticals Ltd.
  • “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Overview
    • Optimistic, Likely and Pessimistic Overview

3. Market Dynamics, Pipeline, and PEST Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • PEST Analysis
  • Pipeline Analysis
  • Initiatives Focusing On PSC Support And Research
  • Reason For Phase 3 Drug Withdrawal
  • Challenges Faced by Orphan Drug Candidates
  • Epidemiology

4. Global Primary Sclerosing Cholangitis Market, By Drug

  • Introduction
  • BTT1023
    • Research Details
  • GS-9674
    • Research Details
  • NGM282
    • Research Details
  • OCA
    • Research Details
  • Cenicriviroc
    • Research Details
  • LUM001
    • Research Details
  • DUR928
    • Research Details
  • norUDCA
    • Research Details
  • HTD1801
    • Research Details
  • IDN-7314
    • Research Details
  • STP705
    • Research Details

5. Global Primary Sclerosing Cholangitis Market, By Region

  • Introduction
  • North America
    • Regional Overview
  • Latin America
    • Regional Overview
  • Europe
    • Regional Overview
  • Asia Pacific
    • Regional Overview
  • Middle East
    • Regional Overview
  • Africa
    • Regional Overview

6. Competitive Landscape

  • Company Profiles
    • Acorda Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Gilead Sciences, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • NGM Biopharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Intercept Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Falk Pharma GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shire Plc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Durect Corporation
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Conatus Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sirnaomics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Shenzhen HighTide Biopharmaceutical Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top
전화 문의
F A Q